Opioids Market By Product Type (Methadone, Codeine, Fentanyl, Oxycodone, Morphine, Hydrocodone, Others), By Application (Pain Management, Cough Treatment, Diarrhea Treatment): Global Opportunity Analysis and Industry Forecast, 2020-2030
Opioids are pain relievers because they include substances that relax muscles and alleviate pain and stress. Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea. Hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are among them. Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain. These analgesics are used to treat severe continuous pain in individuals with terminal conditions and to manage pain in cancer patients.
The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain. Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market. However, emergence and legalization of cannabis as an alternative to opioids impede the growth of the market. On the contrary, increase in consumption of opioids analgesic for pain management in developing countries is anticipated to create lucrative opportunities for market expansion in the near future.
The opioids market is segmented on the basis of type of product, application, and region. According to type of product, the market is classified into codeine, fentanyl, oxycodone, methadone, morphine, hydrocodone, and others. On the basis of application, the market is divided into pain management, cough treatment, and diarrhea treatment. The pain management segment is further divided into neuropathic pain, migraine, back pain, osteoarthritis pain, and cancer pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Purdue Pharma LP, AstraZeneca Plc., C.H. Boehringer Sohn Ag and Ko. Kg, Johnson and Johnson Inc., Sanofi S.A, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Pfizer, Inc., Sun Pharmaceuticals, and Teva Pharmaceuticals.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioids market analysis from 2020 to 2030 to identify the prevailing opioids market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the opioids market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global opioids market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
Pain Management
Cough Treatment
Diarrhea Treatment
By Product Type
Methadone
Codeine
Fentanyl
Oxycodone
Morphine
Hydrocodone
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
India
South Korea
Rest Of Asia Pacific
Japan
China
Australia
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Teva Pharmaceutical Industries Limited
Purdue Pharma LP
AstraZeneca Plc
C.H. Boehringer Sohn Ag and Ko. Kg
Johnson & Johnson, Inc..
Sanofi S.A.
Mallinckrodt Pharmaceuticals
Endo Pharmaceuticals Inc
Pfizer, Inc.
Sun Pharmaceuticals
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.COVID-19 Ipact Analysis
- CHAPTER 4: OPIOIDS MARKET, BY PRODUCT TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Methadone
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Codeine
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Fentanyl
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Oxycodone
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Morphine
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- 4.7 Hydrocodone
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country
- 4.8 Others
- 4.8.1 Key market trends, growth factors and opportunities
- 4.8.2 Market size and forecast, by region
- 4.8.3 Market analysis by country
- CHAPTER 5: OPIOIDS MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Pain Management
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Cough Treatment
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Diarrhea Treatment
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: OPIOIDS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Product Type
- 6.2.3 North America Market size and forecast, by Application
- 6.2.4 North America Market size and forecast, by country
- 6.2.4.1 U.S.
- 6.2.4.1.1 Market size and forecast, by Product Type
- 6.2.4.1.2 Market size and forecast, by Application
- 6.2.4.2 Canada
- 6.2.4.2.1 Market size and forecast, by Product Type
- 6.2.4.2.2 Market size and forecast, by Application
- 6.2.4.3 Mexico
- 6.2.4.3.1 Market size and forecast, by Product Type
- 6.2.4.3.2 Market size and forecast, by Application
- 6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Product Type
- 6.3.3 Europe Market size and forecast, by Application
- 6.3.4 Europe Market size and forecast, by country
- 6.3.4.1 Germany
- 6.3.4.1.1 Market size and forecast, by Product Type
- 6.3.4.1.2 Market size and forecast, by Application
- 6.3.4.2 France
- 6.3.4.2.1 Market size and forecast, by Product Type
- 6.3.4.2.2 Market size and forecast, by Application
- 6.3.4.3 U.K.
- 6.3.4.3.1 Market size and forecast, by Product Type
- 6.3.4.3.2 Market size and forecast, by Application
- 6.3.4.4 Italy
- 6.3.4.4.1 Market size and forecast, by Product Type
- 6.3.4.4.2 Market size and forecast, by Application
- 6.3.4.5 Spain
- 6.3.4.5.1 Market size and forecast, by Product Type
- 6.3.4.5.2 Market size and forecast, by Application
- 6.3.4.6 Rest of Europe
- 6.3.4.6.1 Market size and forecast, by Product Type
- 6.3.4.6.2 Market size and forecast, by Application
- 6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Product Type
- 6.4.3 Asia-Pacific Market size and forecast, by Application
- 6.4.4 Asia-Pacific Market size and forecast, by country
- 6.4.4.1 Japan
- 6.4.4.1.1 Market size and forecast, by Product Type
- 6.4.4.1.2 Market size and forecast, by Application
- 6.4.4.2 China
- 6.4.4.2.1 Market size and forecast, by Product Type
- 6.4.4.2.2 Market size and forecast, by Application
- 6.4.4.3 Australia
- 6.4.4.3.1 Market size and forecast, by Product Type
- 6.4.4.3.2 Market size and forecast, by Application
- 6.4.4.4 India
- 6.4.4.4.1 Market size and forecast, by Product Type
- 6.4.4.4.2 Market size and forecast, by Application
- 6.4.4.5 South Korea
- 6.4.4.5.1 Market size and forecast, by Product Type
- 6.4.4.5.2 Market size and forecast, by Application
- 6.4.4.6 Rest Of Asia Pacific
- 6.4.4.6.1 Market size and forecast, by Product Type
- 6.4.4.6.2 Market size and forecast, by Application
- 6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Product Type
- 6.5.3 LAMEA Market size and forecast, by Application
- 6.5.4 LAMEA Market size and forecast, by country
- 6.5.4.1 Brazil
- 6.5.4.1.1 Market size and forecast, by Product Type
- 6.5.4.1.2 Market size and forecast, by Application
- 6.5.4.2 Saudi Arabia
- 6.5.4.2.1 Market size and forecast, by Product Type
- 6.5.4.2.2 Market size and forecast, by Application
- 6.5.4.3 South Africa
- 6.5.4.3.1 Market size and forecast, by Product Type
- 6.5.4.3.2 Market size and forecast, by Application
- 6.5.4.4 Rest of LAMEA
- 6.5.4.4.1 Market size and forecast, by Product Type
- 6.5.4.4.2 Market size and forecast, by Application
- CHAPTER 7: COMPANY LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Key developments
- CHAPTER 8: COMPANY PROFILES
- 8.1 Teva Pharmaceutical Industries Limited
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
- 8.2 Purdue Pharma LP
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
- 8.3 AstraZeneca Plc
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
- 8.4 C.H. Boehringer Sohn Ag and Ko. Kg
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
- 8.5 Johnson & Johnson, Inc..
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
- 8.6 Sanofi S.A.
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
- 8.7 Mallinckrodt Pharmaceuticals
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
- 8.8 Endo Pharmaceuticals Inc
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
- 8.9 Pfizer, Inc.
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
- 8.10 Sun Pharmaceuticals
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 2. OPIOIDS MARKET REVENUE, FOR METHADONE, BY REGION , 2020-2030,($MILLION)
- TABLE 3. OPIOIDS MARKET FOR METHADONE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. OPIOIDS MARKET REVENUE, FOR CODEINE, BY REGION , 2020-2030,($MILLION)
- TABLE 5. OPIOIDS MARKET FOR CODEINE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. OPIOIDS MARKET REVENUE, FOR FENTANYL, BY REGION , 2020-2030,($MILLION)
- TABLE 7. OPIOIDS MARKET FOR FENTANYL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 8. OPIOIDS MARKET REVENUE, FOR OXYCODONE, BY REGION , 2020-2030,($MILLION)
- TABLE 9. OPIOIDS MARKET FOR OXYCODONE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 10. OPIOIDS MARKET REVENUE, FOR MORPHINE, BY REGION , 2020-2030,($MILLION)
- TABLE 11. OPIOIDS MARKET FOR MORPHINE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 12. OPIOIDS MARKET REVENUE, FOR HYDROCODONE, BY REGION , 2020-2030,($MILLION)
- TABLE 13. OPIOIDS MARKET FOR HYDROCODONE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 14. OPIOIDS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 15. OPIOIDS MARKET FOR OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 16. GLOBAL OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 17. OPIOIDS MARKET REVENUE, FOR PAIN MANAGEMENT, BY REGION , 2020-2030,($MILLION)
- TABLE 18. OPIOIDS MARKET FOR PAIN MANAGEMENT BY COUNTRY, 2020-2030,($MILLION)
- TABLE 19. OPIOIDS MARKET REVENUE, FOR COUGH TREATMENT, BY REGION , 2020-2030,($MILLION)
- TABLE 20. OPIOIDS MARKET FOR COUGH TREATMENT BY COUNTRY, 2020-2030,($MILLION)
- TABLE 21. OPIOIDS MARKET REVENUE, FOR DIARRHEA TREATMENT, BY REGION , 2020-2030,($MILLION)
- TABLE 22. OPIOIDS MARKET FOR DIARRHEA TREATMENT BY COUNTRY, 2020-2030,($MILLION)
- TABLE 23. OPIOIDS MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 24. NORTH AMERICA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 25. NORTH AMERICA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 26. NORTH AMERICA OPIOIDS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 27. U.S. OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 28. U.S. OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 29. CANADA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 30. CANADA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 31. MEXICO OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 32. MEXICO OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 33. EUROPE OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 34. EUROPE OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 35. EUROPE OPIOIDS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 36. GERMANY OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 37. GERMANY OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 38. FRANCE OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 39. FRANCE OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 40. U.K. OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 41. U.K. OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 42. ITALY OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 43. ITALY OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 44. SPAIN OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 45. SPAIN OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 46. REST OF EUROPE OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 47. REST OF EUROPE OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 48. ASIA-PACIFIC OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 49. ASIA-PACIFIC OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 50. ASIA-PACIFIC OPIOIDS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 51. JAPAN OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 52. JAPAN OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 53. CHINA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 54. CHINA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 55. AUSTRALIA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 56. AUSTRALIA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 57. INDIA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 58. INDIA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 59. SOUTH KOREA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 60. SOUTH KOREA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 61. REST OF ASIA PACIFIC OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 62. REST OF ASIA PACIFIC OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 63. LAMEA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 64. LAMEA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 65. LAMEA OPIOIDS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 66. BRAZIL OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 67. BRAZIL OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 68. SAUDI ARABIA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 69. SAUDI ARABIA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 70. SOUTH AFRICA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 71. SOUTH AFRICA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 72. REST OF LAMEA OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
- TABLE 73. REST OF LAMEA OPIOIDS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 74.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 75.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
- TABLE 76.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 77.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES,
- TABLE 78.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
- TABLE 79.PURDUE PHARMA LP: COMPANY SNAPSHOT
- TABLE 80.PURDUE PHARMA LP: OPERATING SEGMENTS
- TABLE 81.PURDUE PHARMA LP: PRODUCT PORTFOLIO
- TABLE 82.PURDUE PHARMA LP: NET SALES,
- TABLE 83.PURDUE PHARMA LP: KEY STRATERGIES
- TABLE 84.ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 85.ASTRAZENECA PLC: OPERATING SEGMENTS
- TABLE 86.ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 87.ASTRAZENECA PLC: NET SALES,
- TABLE 88.ASTRAZENECA PLC: KEY STRATERGIES
- TABLE 89.C.H. BOEHRINGER SOHN AG AND KO. KG: COMPANY SNAPSHOT
- TABLE 90.C.H. BOEHRINGER SOHN AG AND KO. KG: OPERATING SEGMENTS
- TABLE 91.C.H. BOEHRINGER SOHN AG AND KO. KG: PRODUCT PORTFOLIO
- TABLE 92.C.H. BOEHRINGER SOHN AG AND KO. KG: NET SALES,
- TABLE 93.C.H. BOEHRINGER SOHN AG AND KO. KG: KEY STRATERGIES
- TABLE 94.JOHNSON & JOHNSON, INC..: COMPANY SNAPSHOT
- TABLE 95.JOHNSON & JOHNSON, INC..: OPERATING SEGMENTS
- TABLE 96.JOHNSON & JOHNSON, INC..: PRODUCT PORTFOLIO
- TABLE 97.JOHNSON & JOHNSON, INC..: NET SALES,
- TABLE 98.JOHNSON & JOHNSON, INC..: KEY STRATERGIES
- TABLE 99.SANOFI S.A.: COMPANY SNAPSHOT
- TABLE 100.SANOFI S.A.: OPERATING SEGMENTS
- TABLE 101.SANOFI S.A.: PRODUCT PORTFOLIO
- TABLE 102.SANOFI S.A.: NET SALES,
- TABLE 103.SANOFI S.A.: KEY STRATERGIES
- TABLE 104.MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 105.MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 106.MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 107.MALLINCKRODT PHARMACEUTICALS: NET SALES,
- TABLE 108.MALLINCKRODT PHARMACEUTICALS: KEY STRATERGIES
- TABLE 109.ENDO PHARMACEUTICALS INC: COMPANY SNAPSHOT
- TABLE 110.ENDO PHARMACEUTICALS INC: OPERATING SEGMENTS
- TABLE 111.ENDO PHARMACEUTICALS INC: PRODUCT PORTFOLIO
- TABLE 112.ENDO PHARMACEUTICALS INC: NET SALES,
- TABLE 113.ENDO PHARMACEUTICALS INC: KEY STRATERGIES
- TABLE 114.PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 115.PFIZER, INC.: OPERATING SEGMENTS
- TABLE 116.PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 117.PFIZER, INC.: NET SALES,
- TABLE 118.PFIZER, INC.: KEY STRATERGIES
- TABLE 119.SUN PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 120.SUN PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 121.SUN PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 122.SUN PHARMACEUTICALS: NET SALES,
- TABLE 123.SUN PHARMACEUTICALS: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.OPIOIDS MARKET SEGMENTATION
- FIGURE 2.OPIOIDS MARKET,2020-2030
- FIGURE 3.OPIOIDS MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.OPIOIDS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.OPIOIDS MARKET,BY PRODUCT TYPE,2020(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF METHADONE OPIOIDS MARKET,2020-2030(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CODEINE OPIOIDS MARKET,2020-2030(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF FENTANYL OPIOIDS MARKET,2020-2030(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OXYCODONE OPIOIDS MARKET,2020-2030(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MORPHINE OPIOIDS MARKET,2020-2030(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HYDROCODONE OPIOIDS MARKET,2020-2030(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OTHERS OPIOIDS MARKET,2020-2030(%)
- FIGURE 20.OPIOIDS MARKET,BY APPLICATION,2020(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PAIN MANAGEMENT OPIOIDS MARKET,2020-2030(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF COUGH TREATMENT OPIOIDS MARKET,2020-2030(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DIARRHEA TREATMENT OPIOIDS MARKET,2020-2030(%)
- FIGURE 24.OPIOIDS MARKET BY REGION,2020
- FIGURE 25.U.S. OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 26.CANADA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 27.MEXICO OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 28.GERMANY OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 29.FRANCE OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 30.U.K. OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 31.ITALY OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 32.SPAIN OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 33.REST OF EUROPE OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 34.JAPAN OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 35.CHINA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 36.AUSTRALIA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 37.INDIA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 38.SOUTH KOREA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 39.REST OF ASIA PACIFIC OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 40.BRAZIL OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 41.SAUDI ARABIA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 42.SOUTH AFRICA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 43.REST OF LAMEA OPIOIDS MARKET,2020-2030($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48.COMPETITIVE DASHBOARD
- FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ,($MILLION)
- FIGURE 51.PURDUE PHARMA LP.: NET SALES ,($MILLION)
- FIGURE 52.ASTRAZENECA PLC.: NET SALES ,($MILLION)
- FIGURE 53.C.H. BOEHRINGER SOHN AG AND KO. KG.: NET SALES ,($MILLION)
- FIGURE 54.JOHNSON & JOHNSON, INC...: NET SALES ,($MILLION)
- FIGURE 55.SANOFI S.A..: NET SALES ,($MILLION)
- FIGURE 56.MALLINCKRODT PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 57.ENDO PHARMACEUTICALS INC.: NET SALES ,($MILLION)
- FIGURE 58.PFIZER, INC..: NET SALES ,($MILLION)
- FIGURE 59.SUN PHARMACEUTICALS.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook